Table 1 Donor demographics, treatment and CNS collection data for cases from which tissue was collected from BA 9 for this study

From: Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA

Cohort groups

Diagnoses

n

Sex (M/F)

Sui (Y/N)

Age (years)

pH

PMI (hour)

Brain weight (gms)

DOI (years)

APD

ACD

DZD

A

Control

63

47/16

 

43±2

6.33±0.02

41±1.8

1418±19

    
 

Sz

69

51/18

 

44±2

6.31±0.02

40±1.5

1427±20

18±2

624±75

1.7±0.12

13±2.8

 

Def-Sz

20

16/4

7/13

46±4

6.25±0.04

39±2.7

1461±45

20±4

593±124

1.8±0.09

3.5±0.6

 

Non-Def-Sz

49

35/14

26/23

46±2

6.12±0.05

42±2.0

1413±23

18±2

638±94

1.5±0.18

19±4.0

B

Control

15

12/3

 

45±4

6.30±0.05

39±3.8

1355±38

    
 

Sz

27

21/6

 

45±3

6.19±0.05

40±2.8

1393±34

18±3

602±109

1.8±0.10

5.7±1.8

 

Def-Sz

14

11/3

5/9

44±5

6.25±0.06

40±3.5

1425±55

18±4

623±147

1.8±0.12

3.1±0.6

 

Non-Def Sz

13

10/3

3/10

46±5

6.13±0.08

40±4.5

1355±36

18±4

568±169

1.7±0.20

12±4.4

  1. Cohort definitions: Cohort Group A: used for the determination of CHRM1 mRNA and methylation of the promoter region.
  2. Cohort Group B: a subgroup selected at random from cohort A used for studies on miRNAs.
  3. Abbreviations: ACD, last recorded anticholinergic drug doses in benztropine equivalents; APD, last recorded antipsychotic drug doses in chlorpromazine equivalent; Def-Sz, [3H]pirenzepine binding deficient schizophrenia; DOI, duration of illness; DZD, last recorded benzodiazepine doses in diazepam equivalents; F, female; M, male; Non-Def-Sz, subjects with schizophrenia without deficits in [3H]pirenzepine binding; N, no; PMI, postmortem interval; Sui, suicide; Sz, schizophrenia; Y, yes.
Back to article page